This Article Full Text Full Text (PDF) All Versions of this Article: 1535-7163.MCT-06-0494v1 6/3/1013    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Pledgie-Tracy, A. Articles by Davidson, N. E. Search for Related Content PubMed PubMed Citation Articles by Pledgie-Tracy, A. Articles by Davidson, N. E.

Research Articles: Therapeutics, Targets, and Development

Sulforaphane induces cell type–specific apoptosis in human breast cancer cell lines

The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland

Requests for reprints: Nancy E. Davidson, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1550 Orleans Street, CRB-1 Room 409, Baltimore, MD 21231. E-mail: davidna{at}jhmi.edu

Abstract

Sulforaphane, an isothiocyanate found in cruciferous vegetables, has been shown to induce phase 2 detoxication enzymes and inhibit the growth of chemically induced mammary tumors in rats, although the exact mechanisms of action of sulforaphane are not understood. In this study, we evaluated the effects of sulforaphane on cell growth and death in several human breast cancer cell lines and examined the hypothesis that sulforaphane acts as a histone deacetylase (HDAC) inhibitor in these cell lines. Sulforaphane treatment inhibited cell growth, induced a G₂-M cell cycle block, increased expression of cyclin B1, and induced oligonucleosomal DNA fragmentation in the four human breast cancer cell lines examined, MDA-MB-231, MDA-MB-468, MCF-7, and T47D cells. Activation of apoptosis by sulforaphane in MDA-MB-231 cells seemed to be initiated through induction of Fas ligand, which resulted in activation of caspase-8, caspase-3, and poly(ADP-ribose) polymerase, whereas apoptosis in the other breast cancer cell lines was initiated by decreased Bcl-2 expression, release of cytochrome c into the cytosol, activation of caspase-9 and caspase-3, but not caspase-8, and poly(ADP-ribose) polymerase cleavage. Sulforaphane inhibited HDAC activity and decreased the expression of estrogen receptor-, epidermal growth factor receptor, and human epidermal growth factor receptor-2 in each cell line, although no change in the acetylation of H3 or H4 was seen. These data suggest that sulforaphane inhibits cell growth, activates apoptosis, inhibits HDAC activity, and decreases the expression of key proteins involved in breast cancer proliferation in human breast cancer cells. These results support testing sulforaphane in vivo and warrant future studies examining the clinical potential of sulforaphane in human breast cancer. [Mol Cancer Ther 2007;6(3):1013–21]

Grant support: NIH-CA88843 and the Breast Cancer Research Foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 8/14/06; revised 12/ 9/06; accepted 1/31/07.